EUVIMEDEUVIMED entdecken
Crossref

DORAVIR: a French national survey of people with HIV-1 treated with an antiretroviral regimen including doravirine

Cathia Soulie iD, Aliou Balde iD, Djeneba Fofana, Charlotte Charpentier, Pascale Bonnafous, Justine Sourice, Anne De Monte, Véronique Avettand-Fenoel iD, Hélène Le Guillou-Guillemette, Laurence Bocket, Stéphanie Raymond iD, Stéphanie Marque Juillet und 9 weitere

Journal of Antimicrobial Chemotherapy · 2024

DOI: 10.1093/jac/dkae194 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2024. Verfasst von Cathia Soulie und 20 weiteren Autor:innen. Beteiligte Einrichtung: INSERM, Sorbonne Université, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP-HP, Hôpitaux Universitaires Pitié Salpêtrière-Charles Foi…. Hauptthemen laut MEDLINE: HIV-1, HIV Infections, Pyridones, Viral Load. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 23 Literaturangaben. Gefördert von: Agence Nationale de Recherches sur le SIDA et les Hépatites virales, Merck Sharp & Dohme, MSD.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Doravirine is the latest NNRTI to be approved for the treatment of HIV-1 and has a different resistance profile from first-generation NNRTIs. Our aim was to investigate the virological efficacy of antiretroviral treatment including doravirine in people living with HIV-1 (PLWHIV), the factors associated with virological failure (VF) and those associated with the emergence of reverse transcriptase (RT) mutations in the case of VF.

Methods

A retrospective national survey of PLWHIV who were either naive or experienced on antiretroviral treatment including doravirine was conducted. VF was defined as two consecutive plasma viral loads (VLs) of ≥50 copies/mL or one VL of ≥200 copies/mL. Genotypic resistance tests were interpreted using the Stanford (v9.4.1) and ANRS (v33) algorithms.

Results

Of the 589 PLWHIV treated with a doravirine-containing regimen, 8.5% were naive and 91.5% had prior antiretroviral experience; 56.9% were infected with HIV-1 B subtype. Overall, 88.3% and 85.1% of participants were virologically controlled at Month (M)3 and M6 of doravirine treatment, respectively. In multivariable analysis, CRF02_AG subtype, higher zenith plasma HIV-1 RNA VL, doravirine initiation in the context of failure and baseline V179D mutation presence were associated with VF. Among 88 PLWHIV who experienced virological failure at M6, 15.9% had a median of 2 (IQR 1–3) HIV RT mutations. In multivariable analysis, the only factor associated with the occurrence of mutations was a genotypic sensitivity score that was not fully sensitive.

Conclusions

This study is one of the largest to characterize the virological efficacy of doravirine-containing regimens in clinical practice and to identify factors associated with VF or emergence of resistance mutations that should be considered in clinical management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV-1HIV InfectionsPyridonesViral LoadAnti-HIV AgentsDrug Resistance, ViralTriazolesHumansMaleFemaleRetrospective StudiesAdultMiddle AgedFranceGenotypeMutationHIV Reverse TranscriptaseAntiretroviral Therapy, Highly ActiveTreatment Outcome

Substanzen

doravirinePyridonesAnti-HIV AgentsTriazolesHIV Reverse Transcriptase

Autor:innen und Institutionen

  • INSERM, Sorbonne Université, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP-HP, Hôpitaux Universitaires Pitié Salpêtrière-Charles Foix, laboratoire de virologie, Paris, France.
  • INSERM, Sorbonne Université, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France.
  • INSERM, Sorbonne Université, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP-HP, Hôpital Universitaire Saint Antoine, laboratoire de virologie, Paris, France.
  • INSERM UMR 1137 IAME, Université Paris Cité, AP-HP Nord Hôpital Bichat-Claude-Bernard, laboratoire de virologie, Paris, France.
  • CHU Nantes, laboratoire de virologie, Nantes, France.
  • CHU Nice, laboratoire de virologie, Nice, France.

ORCID-Profile: Cathia Soulie, Aliou Balde, Véronique Avettand-Fenoel, Stéphanie Raymond, Elodie Alessandri-Gradt

Förderung

  • Agence Nationale de Recherches sur le SIDA et les Hépatites virales
  • Merck Sharp & Dohme
  • MSD

Zitieren

APA

Soulie, C., Balde, A., Fofana, D., Charpentier, C., Bonnafous, P., Sourice, J., De Monte, A., Avettand-Fenoel, V., Le Guillou-Guillemette, H., Bocket, L., Raymond, S., Marque Juillet, S., Trabaud, M. A., Montes, B., Maillard, A., Hartard, C., Alessandri-Gradt, E., Brochot, E., Signori-Schmuck, A., …, & Marcelin, A. G. (2024). DORAVIR: a French national survey of people with HIV-1 treated with an antiretroviral regimen including doravirine. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkae194

Vancouver

Soulie C, Balde A, Fofana D, Charpentier C, Bonnafous P, Sourice J, et al. DORAVIR: a French national survey of people with HIV-1 treated with an antiretroviral regimen including doravirine. Journal of Antimicrobial Chemotherapy. 2024. doi:10.1093/jac/dkae194

BibTeX
@article{Soulie2024,
  author = {Soulie, Cathia and Balde, Aliou and Fofana, Djeneba and Charpentier, Charlotte and Bonnafous, Pascale and Sourice, Justine and De Monte, Anne and Avettand-Fenoel, Véronique and Le Guillou-Guillemette, Hélène and Bocket, Laurence and Raymond, Stéphanie and Marque Juillet, Stéphanie and Trabaud, Mary-Anne and Montes, Brigitte and Maillard, Anne and Hartard, Cédric and Alessandri-Gradt, Elodie and Brochot, Etienne and Signori-Schmuck, Anne and Assoumou, Lambert and Marcelin, Anne-Geneviève},
  title = {DORAVIR: a French national survey of people with HIV-1 treated with an antiretroviral regimen including doravirine},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2024},
  doi = {10.1093/jac/dkae194}
}
Kostenlos starten →